Cell-based approaches, primarily using mesenchymal stromal cells (MSCs), offers a promising approach toward mitigating the adverse effects of the COVID-19 infection. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. According to the WHO ICTRP and the NIH ClinicalTrials.gov databases, 27 clinical investigations of MSC-based cell therapy approaches have begun in China since the onset of the COVID-19 outbreak, as well as a growing number of academic and industry trials elsewhere. Regenerative medicine & stem cell research is one of the major applications of cell expansion. This is a major indicator of market growth as stem cell-based therapies are showing significant potential in COVID-19 study. In addition to this, various cell expansion products (such as cell culture media) and instruments (such as bioreactors) are being used in COVID-19 research. Hence, the outbreak of COVID-19 has positively impacted the cell expansion.

Cell expansion Market Dynamics
Driver: Increasing incidence of chronic diseases
Cell expansion is used in the R&D of drugs for the treatment of diseases. It is used in the production of vaccines, drugs, therapeutics, and antibiotics. The rising incidence of diseases such as diabetes and cancer has created a need for extensive research to develop new treatment options. According to the International Diabetes Federation (IDF), approximately 425 million people had diabetes in 2017, and this number is estimated to reach 629 million by 2045.

Restraint: Ethical concerns regarding research in cell biology
Research in cell biology necessitates the use of animals and humans, as animal and human cells are used in gene therapy studies that involve the recombination of genes and stem cell research therapies. These cells are also used for in vivo toxicity and pharmacokinetic testing of drugs, which may harm animals and humans.

For More Info, Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194978883

According to India Brand Equity Foundation (IBEF), the biotechnology industry in India is projected to reach USD 100 billion by 2025 from USD 11 billion in 2016, at a growth rate of 30.46%. According to the same source, the pharmaceutical industry in India is projected to reach USD 55 billion by 2020 from USD 36.7 billion in 2016. In Brazil, the pharmaceuticals market is expected to reach USD 29.9 billion by 2021 from USD 25.3 billion in 2016 (Source: Advantage Business Marketing).

Based on the product, the cell expansion market is segmented into consumables and instruments. The consumables segment is further segmented into reagents, media, sera, and disposables, while instruments are segmented into cell expansion supporting equipment, bioreactors, and automated cell expansion systems.

Covid-19 Impact Analysis On The Global Cell Expansion Market

Based on cell type, the cell expansion is segmented into human cells and animal cells. The human cells segment includes stem cells and differentiated cells. The stem cells segment is further classified into adult stem cells, ESCs, and iPSCs. In 2019, the human cells segment accounted for the larger share of the cell expansion market, majorly due to the increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the growing incidence of diseases such as cancer.

North America accounted for the largest share of the cell expansion market in 2019. The large share of this segment can primarily be attributed to the rising incidence of cancer, increasing government funding, rising research activates on stem cell therapies, growing awareness regarding advanced treatment methods, growing geriatric population, and the strong presence of industry players in the region.

The global cell expansion market is dominated by a few globally established players such as Thermo Fisher Scientific (US), Danaher (US), Becton, Dickinson and Company (US), Lonza (Switzerland), Corning (US). Merck (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies Inc. (Canada), Sartorius Stedim Biotech (France), and Terumo (Japan). Start-up companies include REPROCELL (Japan), iXCells Biotechnologies (US), Neuromics (US), G&G technologies (US), and Celltainer Biotech (Netherlands).